Social and behavioral factors associated with failing second-line ART - results from a cohort study at the Themba Lethu Clinic, Johannesburg, South Africa.
Denise EvansSara DahlbergRebecca BerhanuTembeka SinekeCaroline GovathsonIngrid JonkerElisabet LönnermarkMatthew P FoxPublished in: AIDS care (2018)
Poor adherence is a main challenge to successful second-line ART in South Africa. Studies have shown that patients can re-suppress their viral load following intensive adherence counselling. We identify factors associated with failure to re-suppress on second-line ART. The study was a retrospective cohort study which included HIV-positive adults who experienced an elevated viral load ≥400 copies/ml on second-line ART between January 2013-July 2014, had completed an adherence counselling questionnaire and had a repeat viral load result recorded within 6 months of intensive adherence counselling. Log-binomial regression was used to evaluate the association between patient characteristics and social, behavioral or occupational factors and failure to suppress viral load (≥400 copies/ml). A total of 128 patients were included in the analysis, and of these 39% (n = 50) failed to re-suppress their viral load. Compared to those who suppressed, far more patients who failed to suppress reported living with family (44.2% vs. 23.7%), missing a dose in the past week (53.3% vs. 30.0%), using traditional/herbal medications (63.2% vs. 34.3%) or had symptoms suggestive of depression (57.7% vs. 34.3%). These patient-related factors could be targeted for interventions to reduce the risk for treatment failure and prevent switching to expensive third-line ART.
Keyphrases
- south africa
- hiv positive
- antiretroviral therapy
- end stage renal disease
- hiv infected
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- primary care
- men who have sex with men
- peritoneal dialysis
- case report
- depressive symptoms
- clinical trial
- patient reported outcomes
- physical activity
- randomized controlled trial
- hepatitis c virus
- study protocol